Indian drugmakers see U.S. sales hit by delay in new approvals

Indian drugmakers expect a slowdown in new generic drug approvals by the U.S. Food and Drug Administration to weigh on sales in their largest market for at least two more quarters, due to an ongoing overhaul of the review process.

http://in.reuters.com/article/2014/11/12/india-pharmaceuticals-usa-idINKCN0IW02I20141112

YOU ARE BEING REDIRECTED TO THE ARTICLE
. . .
× CLOSE

PROCESSING